SCHEMBL7189787

SCHEMBL7189787

CCOC(=O)C1CC1(F)Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 5/20 0.37
LMNA P02545 3/20 0.37
PPM1B O75688 1/20 0.37
PTPN1 P18031 1/20 0.37
PPP1CC P36873 1/20 0.37
TRPA1 O75762 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
MTOR P42345 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1578042 1.00 MAPT (0.39) MAPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1577514 1.00 MAPT (0.39) MAPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1578216 1.00 MAPT (0.39) MAPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1577775 0.86 PPM1B (0.39) ALDH1A1LMNAPPM1BPTPN1PPP1CC
SCHEMBL3691417 0.85 ALDH1A1 (0.47) MAPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1577887 0.83 ALDH1A1 (0.42) ALDH1A1LMNAL3MBTL1HPGD
SCHEMBL16409442 0.83 LMNA (0.41) MAPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1578269 0.82 EPHX2 (0.43)
SCHEMBL8462991 0.82 ALDH1A1 (0.40) MAPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL18900188 0.82 MAPT (0.38) MAPTCYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10080298-A None JP disclosed
JP-8245500-A None JP disclosed
CN-110483272-B Novel method for asymmetric synthesis of (1S,2S) -2-fluorocyclopropanecarboxylic acid by catalysis of chiral rhodium catalyst 广州康瑞泰药业有限公司 2022-09-27 CN disclosed
US-10385000-B2 Method for synthesizing 2-fluorocyclopropane carboxylic acid CHEN-STONE (GUANGZHOU) CO., LTD. (CN) 2019-08-20 US disclosed
EP-2651899-B1 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF HOFFMANN LA ROCHE (CH) 2017-05-31 EP disclosed
EP-2651899-B1 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF HOFFMANN LA ROCHE (CH) 2017-05-31 EP disclosed
US-20160060262-A1 Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof GENENTECH, INC. (US) 2016-03-03 US disclosed
US-20160060262-A1 Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof GENENTECH, INC. (US) 2016-03-03 US disclosed
US-20160060262-A1 Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof GENENTECH, INC. (US) 2016-03-03 US disclosed
US-9206175-B2 Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof GENENTECH, INC. (US) 2015-12-08 US disclosed
US-6596898-B2 Making a 2-fluoro-2-chlorocyclopropanecarboxylic acid derivative stereoselectively in high yield by reacting a diazoacetic acid derivative with 1-fluoro-1-chloroethylene using metal catalyst having chiral ligands DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-07-22 US disclosed
US-20010051750-A1 PROCESS FOR PREPARING HALOGENATED CYCLOPROPANE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-12-13 US disclosed
EP-0858992-B1 PROCESS FOR PRODUCING HALOGENATED CYCLOPROPANE DERIVATIVES DAIICHI SEIYAKU CO (JP) 2001-12-12 EP disclosed
US-6130350-A Process for producing 2-fluorine-1-cyclopropane carboxylic acid derivatives by reductive dehalogenation BAYER AKTIENGESELLSCHAFT (DE) 2000-10-10 US disclosed
EP-0712831-B1 SELECTIVE DEHALOGENATION METHOD DAIICHI SEIYAKU CO (JP) 1999-11-03 EP disclosed
EP-0858992-A1 PROCESS FOR PRODUCING HALOGENATED CYCLOPROPANE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1998-08-19 EP disclosed
US-5780669-A Selective dehalogenation process DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1998-07-14 US disclosed
JP-H1080298-A PRODUCTION OF OPTICALLY ACTIVE SUBSTANCE OF 2-HALO-2-FLUOROCYCLOPROPANECARBOXYLIC ACID SUMITOMO CHEM CO LTD 1998-03-31 JP disclosed
JP-H08245500-A PRODUCTION OF 2-FLUOROCYCLOPROPANECARBOXYLIC ACIDS SUMITOMO CHEM CO LTD 1996-09-24 JP disclosed
EP-0712831-A1 SELECTIVE DEHALOGENATION METHOD DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1996-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385000-B2 Method for synthesizing 2-fluorocyclopropane carboxylic acid FOSB, FDPS, PFAS MAPT 4383/4885CYP3A4 767/4885CYP2D6 1203/4885
US-20160060262-A1 Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof XDH, CYP2B6, COX6B1 MAPT 4200/4885CYP3A4 27/4885CYP2D6 4/4885
US-20010051750-A1 PROCESS FOR PREPARING HALOGENATED CYCLOPROPANE DERIVATIVES CYP2F1, CYP4F2, CYP4F8 MAPT 4557/4885CYP3A4 44/4885CYP2D6 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.